Germany Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Germany Pharmaceuticals and Healthcare Report

Germany Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Germany Pharmaceuticals and Healthcare Report
Published Sep 10, 2016
103 pages — Published Sep 10, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. Also in July, Heidelberg Pharma (Wilex) and Advanced Proteome Therapeutics entered into a partnership that will test the combination of Advanced Proteome Therapeutic s proprietary site-specific protein modification technology and Heidelberg Pharma s proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs). ...In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. Also in July, Heidelberg Pharma (Wilex) and Advanced Proteome Therapeutics entered into a partnership that will test the combination of Advanced Proteome Therapeutic s proprietary site-specific protein modification technology and Heidelberg Pharma s proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs). As of information reported in June ----, Boehringer Ingelheim and Inventiva are to enter into a new multi-year R&D drug discovery collaboration and licensing agreement, which reflects Boehringer Ingelheim intent to stablish a dominant position in the niche market of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. ...As of information reported in June ----, Boehringer Ingelheim and Inventiva are to enter into a new multi-year R&D drug discovery collaboration and licensing agreement, which reflects Boehringer Ingelheim intent to stablish a dominant position in the niche market of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. In May ----, Iceland-based Alvotech entered into a definitive agreement to acquire Germany-based Baliopharm GmbH, previously a subsidiary of Baliopharm AG, an operation that will provide Alvotech with complementary capabilities in the area of biosimilar development.

...In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. In June ----, the German Federal Supreme Court granted Eli Lilly s appeal in its case against Actavis (Allergan), vacating the prior decision that had denied patent infringement. ...In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. In June ----, the German Federal Supreme Court granted Eli Lilly s appeal in its case against Actavis (Allergan), vacating the prior decision that had denied patent infringement. The case centres on whether Lilly s patent for Alimta (pemetrexed disodium) would be infringed by Actavis proposed generic competitor in Germany. ...The case centres on whether Lilly s patent for Alimta (pemetrexed disodium) would be infringed by Actavis proposed generic competitor in Germany.

...BMI View: Germany s large and expanding pharmaceutical market will continue to generate commercial opportunities for drugmakers over the forecast period. While Germany s ongoing economic rebalancing will continue to support robust domestic consumption indices, including in health sector segments, healthcare spending will also be driven by population growth owing to net migration in the medium term. ...

  
Source:
Document ID
1748-1899
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Germany Pharmaceuticals and Healthcare Report" Sep 10, 2016. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Germany-Pharmaceuticals-and-Healthcare-Report-2026-288>
  
APA:
Business Monitor International - Industry Reports. (2016). Germany Pharmaceuticals and Healthcare Report Sep 10, 2016. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Germany-Pharmaceuticals-and-Healthcare-Report-2026-288>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.